Direct UHPLC-DAD Method to Determine Asenapine, Paroxetine and Fluvoxamine in Human Blood Serum, Urine and Cerebrospinal Fluid

Author(s): Leda Kovatsi, Natalia Manousi, Ioannis Papadoyannis

Journal Name: Current Pharmaceutical Analysis

Volume 12 , Issue 4 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Asenapine is a new antipsychotic drug used in the treatment of schizophrenia and bipolar disorder. Paroxetine and fluvoxamine are second generation antidepressant drugs.

Objective: Herein we have developed a simple and rapid UHPLC-DAD method to determine asenapine, fluvoxamine and paroxetine. The methodology was applied to the analysis of human biofluids, namely blood serum, urine and cerebrospinal fluid.

Method: The analytes of interest were separated on an Inertsil C8, (250 x 4.0 mm) 5 µm, analytical column, using mobile phase consisted of acetate buffer (0.2 M, pH=4.5), methanol and acetonitrile (60:10:30 % v/v). Isocratic elution was performed at a flow rate of 1.7 mL/min. Photodiode array detection was applied at 231 nm for asenapine, 294 nm for paroxetine and 251 nm for fluvoxamine. Sulfadimethoxine (2.5 ng/µL) was chosen as the internal standard. The method was validated in terms of linearity, selectivity, accuracy, precision and stability.

Results: Limits of detection and quantitation were 0.03 ng/µL, and 0.10 ng/µL respectively, using the S/N= 3.3 and S/N= 10 criteria.

Conclusion: The developed method is consistent and can be used as a useful analytical tool to monitor the three drugs in serum, urine and cerebrospinal fluid, in patients under treatment.

Keywords: Asenapine, biofluids, fluvoxamine, paroxetine, cerebrospinal fluid, UHPLC.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 22 September, 2016
Page: [349 - 356]
Pages: 8
DOI: 10.2174/1573412912666151217182814
Price: $65

Article Metrics

PDF: 26